<DOC>
	<DOC>NCT00482248</DOC>
	<brief_summary>This study will assess further the safety and tolerability of long-term treatment with omalizumab by extending omalizumab treatment by 1 year for those patients with allergic asthma who successfully completed study CIGE25011E2.</brief_summary>
	<brief_title>Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Patients with a history of severe allergic asthma who completed the treatment period of CIGE250011E3 protocol, without experiencing any significant drugrelated adverse events Male or female patients 1275 years of age who have given written informed consent approved by the ethical committee Patients who had not received study medication for greater than 84 days since visit 38 of study CIGE240011E3 Pregnant females or nursing mothers Patients with know hypersensitivity to any ingredients of Omalizumab or related drugs Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>anti-immunoglobulin E</keyword>
	<keyword>omalizumab</keyword>
	<keyword>allergic asthma</keyword>
</DOC>